NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Cancer Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Breast Cancer



Genomic Health Reports Recommendation of Oncotype DX(R) in National Comprehensive Cancer Network Guidelines



January 15th, 2008

Genomic Health, Inc. (NASDAQ:GHDX) reported that the company's Oncotype DX(R) breast cancer assay, used to predict the likelihood of disease recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients, has been included in the National Comprehensive Cancer Network (NCCN) 2008 Breast Cancer Treatment Guidelines. Oncotype DX is the only multi-gene expression assay to be recommended by NCCN, an alliance of 21 world-leading cancer centers dedicated to improving the quality and effectiveness of care provided to patients with cancer. These guidelines were published online at http://www.nccn.org/.

"We are pleased that NCCN, a...


Source: Cancer Weekly (2008-01-15)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login